Nov 15, 2005
Invitrogen announced the acquisitions of Quantum Dot Corp. and the BioPixels business unit of BioCrystal Ltd. and the early closing of the Biosource International acquisition. The acquisitions bolster Invitrogen’s molecular probes business in advanced labeling and detection technologies, the company says.
CombinatoRx and Angiotech Pharmaceuticals announced a multi-year research and license agreement for the discovery, development, and potential commercialization by Angiotech of drug devices and interventional medicine products built from innovative drug combinations. The initial focus is on vascular, orthopedic, and general surgery indications.
Caliper Life Sciences announced the closing of its planned acquisition for $22 million of NovaScreen BioSciences. The acquisition combines NovaScreen’s screening, profiling, and assay development services with Caliper’s LabChip and liquid handling products.
Rosetta Biosoftware and Agendia will work together to deliver novel diagnostics tools that will be made available in the Rosetta Resolver system for gene expression data analysis.